De rol van het hormoon TSH in het immuunsysteem.
- Conditions
- immunodeficienciesT cell development
- Registration Number
- NL-OMON20628
- Lead Sponsor
- Erasmus Medical Center, Rotterdam, The Netherlands
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
1. Have the capacity to understand and willingness to sign an informed consent form;
2. Have been medically treated for primary hypothyroidism for the last 6 months with only thyroxin substitution therapy;
Exclusion Criteria
1. Uncontrolled hypothyroidism;
2. Presence of antibodies to the TSH receptor;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary endpoint consist of a change in thymic output, peripheral cell numbers or ratio’s of peripheral T cell<br>subpopulations in response to treatment with rhTSH. T cell subpopulations will be defined using flow<br>cytometry. Moreover thymic output will be measured using TREC analysis.
- Secondary Outcome Measures
Name Time Method Secondary endpoints are:<br /><br>1. Lipid metabolism;<br /><br>2. Bone metabolism;<br /><br>3. CK levels;<br /><br>4. Urine metabolites.